EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
Just Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
- Just Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
The issuer is solely responsible for the content of this announcement. - Plague, an infectious disease caused by the bacterium Yersinia pestis (Y. pestis), is one of the designated targets of interest under the DODs Accelerated Antibodies Program.
- The advanced Just Evotec Biologics platform is specifically well suited for monoclonal antibodies as well as other protein modalities such as Fc fusion proteins.
- Just Evotec Biologics J.POD Redmond, Washington biologics development and cGMP manufacturing facility will develop mAb-based drug products for the US Department of Defense.